Interferon ß in treatment of COVID-19
Phase 2
Recruiting
- Conditions
- COVID-19 pneumonia.
- Registration Number
- IRCT20100228003449N27
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Patients with highly suspected or confirmed COVID-19 who are candid for hospitalization and starting triple-drug combination.
Exclusion Criteria
History of drug allergy
Pregnancy and lactation
Uncontrolled baseline diseases including neuropsychiatric disorders, diabetes, thyroid disorders, heart disease, baseline liver failure
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response to the treatment. Timepoint: Daily. Method of measurement: According the clinical, paraclinical and laboratory findings.;Complications of the treatment. Timepoint: Daily. Method of measurement: Interview and patient's record.
- Secondary Outcome Measures
Name Time Method Duration of hospitalization. Timepoint: End of the treatment. Method of measurement: Patient's record.;Clinical outcome. Timepoint: End of treatment. Method of measurement: Patient's record.